Literature DB >> 26456805

Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) receptors.

Jeffrey S Stehouwer1, Chase H Bourke2, Michael J Owens2, Ronald J Voll3, Clinton D Kilts4, Mark M Goodman5.   

Abstract

Compounds 1-14 were synthesized in a search for high-affinity CRF1 receptor ligands that could be radiolabeled with (11)C or (18)F for use as positron emission tomography (PET) radiotracers. Derivatives of 2 were developed which contained amide N-fluoroalkyl substituents. Compounds [(18)F]24 and [(18)F]25 were found to have appropriate lipophilicities of logP7.4=2.2 but microPET imaging with [(18)F]25 demonstrated limited brain uptake.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CRF-1 receptor; Corticotropin-releasing factor; Fluorine-18; PET imaging; Positron emission tomography

Mesh:

Substances:

Year:  2015        PMID: 26456805      PMCID: PMC4628894          DOI: 10.1016/j.bmcl.2015.10.010

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

Review 1.  The role of corticotropin-releasing factor in drug addiction.

Authors:  Z Sarnyai; Y Shaham; S C Heinrichs
Journal:  Pharmacol Rev       Date:  2001-06       Impact factor: 25.468

Review 2.  International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands.

Authors:  Richard L Hauger; Dimitri E Grigoriadis; Mary F Dallman; Paul M Plotsky; Wylie W Vale; Frank M Dautzenberg
Journal:  Pharmacol Rev       Date:  2003-03       Impact factor: 25.468

Review 3.  Brain receptor imaging.

Authors:  Wolf-Dieter Heiss; Karl Herholz
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

Review 4.  Physiology and pharmacology of corticotropin-releasing factor.

Authors:  M J Owens; C B Nemeroff
Journal:  Pharmacol Rev       Date:  1991-12       Impact factor: 25.468

5.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

Authors:  W Vale; J Spiess; C Rivier; J Rivier
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

Review 6.  Progress in corticotropin-releasing factor-1 antagonist development.

Authors:  Eric P Zorrilla; George F Koob
Journal:  Drug Discov Today       Date:  2010-03-03       Impact factor: 7.851

7.  On quantitative relationships between drug-like compound lipophilicity and plasma free fraction in monkey and human.

Authors:  Sami S Zoghbi; Kacey B Anderson; Kimberly J Jenko; David A Luckenbaugh; Robert B Innis; Victor W Pike
Journal:  J Pharm Sci       Date:  2011-12-13       Impact factor: 3.534

Review 8.  PET radiotracers: crossing the blood-brain barrier and surviving metabolism.

Authors:  Victor W Pike
Journal:  Trends Pharmacol Sci       Date:  2009-07-16       Impact factor: 14.819

9.  Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims.

Authors:  C B Nemeroff; M J Owens; G Bissette; A C Andorn; M Stanley
Journal:  Arch Gen Psychiatry       Date:  1988-06

10.  Synthesis and in vivo evaluation of [11C]SN003 as a PET ligand for CRF1 receptors.

Authors:  J S Dileep Kumar; Vattoly J Majo; Gregory M Sullivan; Jaya Prabhakaran; Norman R Simpson; Ronald L Van Heertum; J John Mann; Ramin V Parsey
Journal:  Bioorg Med Chem       Date:  2006-03-10       Impact factor: 3.641

View more
  2 in total

Review 1.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

2.  Differential sensitivity of alcohol drinking and partner preference to a CRFR1 antagonist in prairie voles and mice.

Authors:  Sheena Potretzke; Meridith T Robins; Andrey E Ryabinin
Journal:  Horm Behav       Date:  2020-01-13       Impact factor: 3.587

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.